ClinicalTrials.gg
CompletedNCT07140822Updated Aug 26, 2025

A Randomized Study of Cutting Balloon Catheter for CAD

An interventional study of Coronary Cutting Balloon Catheter and VesscideTM Cutting Balloon System in Coronary Artery Disease, Percutaneous Coronary Intervention (PCI) and Calcified Coronary Lesions, sponsored by Shanghai Shenqi Medical Technology Co., Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-08-26.

Sponsored by Shanghai Shenqi Medical Technology Co., Ltd · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 2 years 3 months after the study started (first participant enrolled Apr 2023, registered Aug 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
166
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 543 studies in Coronary Artery Disease with a site in China — 176 open to participants now, 210 under way, 6 of them phase 3. Coronary Artery Disease · China.

Enrollment
222nd of 324
166 · median 307
Started
2023
with 44 others
No phase
210 of 543
71 open now
Registered
462nd of 543
by date

Among the 543 studies in Coronary Artery Disease with a site in China, this one is the 222nd largest by enrollment of the 324 interventional ones that give a count, is one of 45 that started in 2023, is one of 210 with no phase, and was the 462nd registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

176 of the 543 studies in Coronary Artery Disease with a site in China are open now. Recruiting first, the newest first:

171 more — sign in →

All 176 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 543 studies in Coronary Artery Disease with a site in China, or all of them as a file.
02

Study summary

This study is designed as a prospective, multi-center, non-inferiority and randomized controlled clinical trial. A total of 158 eligible subjects from 18 sites across the country is planned to be enrolled, and they will be randomly assigned to the test group and the control group according to a ratio of 1:1 for balloon dilatation for the treatment of coronary artery disease.

03

Conditions studied

  • Coronary Artery Disease
  • Percutaneous Coronary Intervention (PCI)
  • Calcified Coronary Lesions
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Subjects aged 18-80 years, including 18 and 80 years;
  • Patients with stable or unstable angina, or old myocardial infarction or clinically judged silent myocardial ischemia (target vessel reference vessel diameter 2.00-4.00 mm (both inclusive)), luminal diameter stenosis ≥ 70%, or ≥ 50% by visual inspection with evidence of ischemia, TIMI blood flow ≥ grade 1, and requiring treatment with a cutting balloon dilatation catheter as considered by the operator;
  • Able to understand the purpose of the study, participate the study willingly, sign the written form, and are available for and willing to follow-up as defined in this trial.

General exclusion criteria:

  1. Pregnant or lactating women or women who are planning pregnancy;
  2. Subjects with myocardial infarction occurred within one week; the myocardial enzyme TNI or TNT has not returned to normal although myocardial infarction has occurred for more than one week;
  3. Subjects who are considered by the investigator through angiography that the cutting balloon cannot pass through even dilatation with a small one and need a rotational atherectomy;
  4. Non-target vessels, which can be treated simultaneously with the target blood vessel, have not been treated well in advance, or the total number of lesions on the non-target blood vessel is > 3;
  5. Class IV patients;
  6. Patients with severe renal failure (creatinine > 443 μmol/L) or ongoing hemodialysis therapy;
  7. Heart transplant patients;
  8. Patients with graft vessel disease;
  9. Patients with hemodynamic instability or symptoms of shock;
  10. Patients with a of no more than 1 year;
  11. Patients who are expected to undergo elective surgery within 1 month;
  12. Patients not eligible for coronary artery bypass grafting (CABG) procedure;
  13. Patients with a predisposition to bleeding, a history of active peptic ulcer, or to antiplatelet agents and anticoagulants, patients who cannot undergo anticoagulant therapy, or patients who have experienced hemorrhagic stroke within 6 months;
  14. Patients who are known to be allergic or contraindicated to heparin, contrast agents, etc.;
  15. Patients who are suffering from diseases that can cause difficulties in treatment and evaluation;
  16. Patients who have been selected and have participated in trials with other drug or medical device but have not reached the time limit of the primary study endpoint;
  17. Clinicians expect that the risk of interventional surgery is extremely high or other cases that should be ruled out;
  18. Patients who, in the judgment of the investigator, are poor compliance with the therapy and are unable to complete the trial as required;

    Lesion related exclusion criteria:

  19. Left main lesion or lesion at a distance of ≤ 2 mm from the left main coronary artery;
  20. Patients with thrombosis suggested by angiography;
  21. Patients with a total occluded lesion and a TIMI flow grade 0;
  22. Coronary artery spasm (CAS) without organic stenosis;
  23. Left main lesion without protection from bypass grafts or collateral flow;
  24. In addition to the above contraindications, conditions diagnosed by the physician as unsuitable for the use of the device.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
166 participants (actual)

Study arms

  • Experimental
    Coronary Cutting Balloon Catheter

    Device: Coronary Cutting Balloon Catheter

  • Active comparator
    VesscideTM Cutting Balloon System

    Device: VesscideTM Cutting Balloon System

Interventions

  • DeviceCoronary Cutting Balloon Catheter

    This product uses a pressure device to pressurize the balloon to expand it. The blades designed on the surface of the balloon produce a cutting effect on the vascular lesions, allowing it to better embed into the plaque.

  • DeviceVesscideTM Cutting Balloon System

    This product utilizes a pressure mechanism to inflate the balloon, causing it to expand. The blades on the balloon's surface create a cutting action on the vascular lesions, enabling the device to penetrate the plaque more effectively.

06

What researchers measure

Primary outcomes

  1. Acute gain

    The acute gain is defined as the difference in minimal lumen diameter (MLD) of the target lesions measured by quantitative coronary angiography (QCA) before and after the balloon dilatation using balloons from the test group/control group.

    Time frame: Before and after balloon dilation

07

Study locations

1 site
  • Meizhou People's Hospital
    Meizhou, Guangdong 514031, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2023 to primary completion in Jul 2023, 2 months.

Of 177 industry-sponsored interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 40. This study's 2 months is below that.

Counting every sponsor, half of 933 studies reached it within 30 months; a quarter within 15 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2025
First posted
Aug 26, 2025
StartActual
Apr 26, 2023
Primary completionActual
Jul 24, 2023
CompletionActual
Oct 10, 2023
Last update
Aug 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07140822
Lead sponsor
Shanghai Shenqi Medical Technology Co., Ltd
Responsible party
Sponsor
First posted
Aug 26, 2025
Start date
Apr 26, 2023
Primary completion
Jul 24, 2023
Completion
Oct 10, 2023
Last update
Aug 26, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion